Dong Wha Pharmaceutical Co. Ltd.

Quick facts

Marketed products

• DW6012(Dasidiem tab. 10/100mg) · Oncology
  DW6012 is a fixed-dose combination of dasatinib and another agent that inhibits tyrosine kinases to suppress abnormal cell proliferation.

Phase 1 pipeline

• Aceclofenac and Esomeprazole · Gastroenterology
  Inhibits COX-2 and blocks the action of prostaglandins, thereby reducing inflammation and pain, and also inhibits the proton pump in the stomach, thereby reducing acid production.
• Clozaril · Neuroscience
• DW6012
• DW6013
• DW6014
• DWCZP
• DWETR10
• DWETR25

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Dong Wha Pharmaceutical Co. Ltd. portfolio CI brief
• Dong Wha Pharmaceutical Co. Ltd. pipeline updates RSS